Plasma Chromogranin B as a Marker of Tumor Burden and Radiological Progression in Neuroendocrine Tumors


Introduction: Chromogranin-B (CgB) is expressed in most neuroendocrine tumors (NETs), yet little is understood about its clinical utility as a biomarker.

Aim(s): To investigate the role of CgB in follow-up of NET patients.

Materials and methods: Two-hundred and twelve patients [167 with midgut (mNETs), 45 pancreatic (pNETs)] with elevated plasma CgB levels were included. Correlations between CgB (normal <150pmol/L), tumor burden and histological grade, as well as its predictive value for radiological progression (RP), were investigated.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Braude D, Bartholomew T, Rossi R, Garcia-Hernandez J, Mullan M,

Keywords: Chromogranin B, midgut NETs, pancreatic NET, progression,

To read the full abstract, please log into your ENETS Member account.